The Emerging Role of Cetuximab in Head and Neck Cancer: A 2007 Perspective

REFERENCES

• Wong S. F. Cetuximab: an epidermal growth factor receptor monoclonal antibody for the treatment of colorectal cancer. Clin. Ther. 2005; 27: 684–94
   PubMed Web of Science ®Google Scholar
• Jemal A., et al. Cancer statistics, 2007. CA Cancer J. Clin. 2007; 57: 46–66
   Google Scholar
• Adelstein D. J., et al. An intergroup phase III comparison of standard radiation therapy and two schedules of concurrent chemoradiotherapy in patients with unresectable squamous cell head and neck cancer. J. Clin. Oncol. 2003; 21(1)92–98
   PubMed Web of Science ®Google Scholar
• Bourhis J, et al. Update of MACH-NC (Meta-analysis of chemotherapy in head & neck cancer) database focused on concomitant chemoradiotherapy. J. Clin. Oncol. 2004, ASCO Annual Meeting Proceedings (Post-Meeting Edition). Vol 22, No 14 S (July 15 Supplement), 2004: 5505
   PubMedGoogle Scholar
• Kufe D. W., et al. Cancer medicine 6. 6th ed. BC Decker. 2 v, Hamilton, Ont. London 2003
   Google Scholar
• Browman G. P., Cronin L. Standard chemotherapy in squamous cell head and neck cancer: what we have learned from randomized trials. Semin. Oncol. 1994; 21(3)311–9
   PubMed Web of Science ®Google Scholar
• Gibson M. K., et al. Randomized phase III evaluation of cisplatin plus fluorouracil versus cisplatin plus paclitaxel in advanced head and neck cancer (E1395): an intergroup trial of the Eastern Cooperative Oncology Group. J. Clin. Oncol. 2005; 23(15)3562–7
   PubMed Web of Science ®Google Scholar
• Colevas A. D. Chemotherapy options for patients with metastatic or recurrent squamous cell carcinoma of the head and neck. J. Clin. Oncol. 2006; 24: 2644–52
   PubMed Web of Science ®Google Scholar
• Leon X., et al. A retrospective analysis of the outcome of patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck refractory to a platinum-based chemotherapy. Clin. Oncol. (R Coll Radiol) 2005; 17(6)418–24
   PubMed Web of Science ®Google Scholar
• Vermorken J., et al. Cetuximab in recurrent/metastatic squamous cell carcinoma of the head and neck refractory to first-line platinum-based therapies. J. Clin. Oncol. 2005; 23: 5505, (16 suppl)
   Google Scholar
• Vermorken J. B., et al. Open-label, uncontrolled multicenter phase II study ot evaluate the efficacy and toxicity of cetuximab as a single agent in patients with recurrent and/ot matastatic squamous cell carcinoma of the head and neck who failed to respond to platinum-based therapy. J. Clin. Oncol. 2007; 2171–7
   PubMed Web of Science ®Google Scholar
• Baselga J., et al. Phase II multicenter study of the antiepidermal growth factor receptor monoclonal antibody cetuximab in combination with platinum-based chemotherapy in patients with platinum-refractory metastatic and/or recurrent squamous cell carcinoma of the head and neck. J. Clin. Oncol. 2005; 23(24)5568–77
   PubMed Web of Science ®Google Scholar
• Cohen S. The stimulation of epidermal proliferation by a specific protein (EGF). Developmental Biology 1965; 12(3)394–407
   PubMed Web of Science ®Google Scholar
• Cohen S., Carpenter G., King L., Jr. Epidermal growth factor-receptor-protein kinase interactions. Co-purification of receptor and epidermal growth factor-enhanced phosphorylation activity. Journal of Biological Chemistry 1980; 255: 4834–42
   PubMed Web of Science ®Google Scholar
• Masui H., et al. Growth inhibition of human tumor cells in athymic mice by anti-epidermal growth factor receptor monoclonal antibodies. Cancer Research 1984; 44(3)1002–7
   PubMed Web of Science ®Google Scholar
• Mendelsohn J. Growth factor receptors as targets for antitumor therapy with monoclonal antibodies. Progress in Allergy 1988; 45: 147–60
   PubMedGoogle Scholar
• Goldstein N. I., et al. Biological efficacy of a chimeric antibody to the epidermal growth factor receptor in a human tumor xenograft model. Clin. Cancer Res. 1995; 1(11)1311–8
   PubMed Web of Science ®Google Scholar
• Sato J. D., et al. Biological effects in vitro of monoclonal antibodies to human epidermal growth factor receptors. Mol. Biol. Med. 1983; 1(5)511–29
   PubMedGoogle Scholar
• Fan Z., et al. Antitumor effect of anti-epidermal growth factor receptor monoclonal antibodies plus cis-diamminedichloroplatinum on well established A431 cell xenografts. Cancer Research 1993; 53(19)4637–42
   PubMed Web of Science ®Google Scholar
• Baselga J., et al. Antitumor effects of doxorubicin in combination with anti-epidermal growth factor receptor monoclonal antibodies. Journal of the National Cancer Institute 1993; 85(16)1327–33
   PubMed Web of Science ®Google Scholar
• Balaban N., et al. The effect of ionizing radiation on signal transduction: antibodies to EGF receptor sensitize A431 cells to radiation. Biochimica. et. Biophysica. Acta. 1996; 1314(1–2)147–56
   PubMed Web of Science ®Google Scholar
• Schmidt-Ullrich R. K., et al. Radiation-induced proliferation of the human A431 squamous carcinoma cells is dependent on EGFR tyrosine phosphorylation. Oncogene 1997; 15(10)1191–7
   PubMed Web of Science ®Google Scholar
• Knebel A., et al. Dephosphorylation of receptor tyrosine kinases as target of regulation by radiation, oxidants or alkylating agents. Embo. J. 1996; 15(19)5314–25
   PubMed Web of Science ®Google Scholar
• Sheridan M. T., et al. Potential indicators of radiosensitivity in squamous cell carcinoma of the head and neck. Radiation Oncology Investigations 1997; 5(4)180–6
   PubMedGoogle Scholar
• Huang S., Bock J. M., Harari P. M. Epidermal growth factor receptor blockade with C225 modulates proliferation, apoptosis, and radiosensitivity in squamous cell carcinomas of the head and neck. Cancer Research 1999; 59(8)1935–40
   PubMed Web of Science ®Google Scholar
• Saleh M. N., et al. Combined modality therapy of A431 human epidermoid cancer using anti- EGFr antibody C225 and radiation. Cancer Biother. Radiopharm. 1999; 14(6)451–63
   PubMed Web of Science ®Google Scholar
• Huang S., Harari P. M. Epidermal growth factor receptor inhibition in cancer therapy: biology, rationale and premininary clinical results. Investigational New Drugs 1999; 17: 259–69
   PubMed Web of Science ®Google Scholar
• Bianco C., et al. Antitumor activity of combined treatment of human cancer cells with ionizing radiation and anti-epidermal growth factor receptor monoclonal antibody C225 plus type I protein kinase A antisense oligonucleotide. Clin. Cancer Res. 2000; 6(11)4343–50
   PubMed Web of Science ®Google Scholar
• Huang S.-M., Harari P. M. Modulation of Radiation Response after Epidermal Growth Factor Receptor Blockade in Squamous Cell Carcinomas: Inhibition of Damage Repair, Cell Cycle Kinetics, and Tumor Angiogenesis. Clin. Cancer Res. 2000; 6(6)2166–74
   PubMed Web of Science ®Google Scholar
• Milas L., et al. In vivo enhancement of tumor radioresponse by C225 antiepidermal growth factor receptor antibody. Clin. Cancer Res. 2000; 6(2)701–8
   PubMed Web of Science ®Google Scholar
• Rao G. S., Murray S., Ethier S. P. Radiosensitization of human breast cancer cells by a novel ErbB family receptor tyrosine kinase inhibitor. International Journal of Radiation Oncology, Biology, Physics 2000; 48(5)1519–28
   PubMed Web of Science ®Google Scholar
• Harari P., Huang S. Modulation of molecular targets to enhance radiation. Clinical Cancer Research 2000; 6: 323–25
   PubMed Web of Science ®Google Scholar
• Harari P. M., Huang S. Head and neck cancer as a clinical model for molecular targeting of therapy: combining EGFR blockade with radiation. International Journal of Radiation Oncology, Biology, Physics 2001; 49(2)427–33
   PubMed Web of Science ®Google Scholar
• Bianco C., et al. Enhancement of Antitumor Activity of Ionizing Radiation by Combined Treatment with the Selective Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor ZD1839 (Iressa). Clin. Cancer Res. 2002; 8(10)3250–8
   PubMed Web of Science ®Google Scholar
• Huang S., et al. Modulation of radiation response and tumor-induced angiogenesis after epidermal growth factor receptor Inhibition by ZD1839 (Iressa). Cancer Res. 2002; 62(15)4300–6
   PubMed Web of Science ®Google Scholar
• Williams K. J., et al. ZD1839 (‘Iressa’), a specific oral epidermal growth factor receptor-tyrosine kinase inhibitor, potentiates radiotherapy in a human colorectal cancer xenograft model. British Journal of Cancer 2002; 86(7)1157–61
   PubMed Web of Science ®Google Scholar
• She Y. H., et al. The epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 selectively potentiates, radiation response of human tumors in nude mice, with a marked improvement in therapeutic index. Clinical Cancer Research 2003; 9: 3773–8, (10 Part 1)
   PubMed Web of Science ®Google Scholar
• Shintani S., et al. Enhancement of tumor radioresponse by combined treatment with gefitinib (Iressa, ZD1839), an epidermal growth factor receptor tyrosine kinase inhibitor, is accompanied by inhibition of DNA damage repair and cell growth in oral cancer. International Journal of Cancer 2003; 107(6)1030–7
   PubMed Web of Science ®Google Scholar
• Solomon B., et al. EGFR blockade with ZD1839 (“Iressa”) potentiates the antitumor effects of single and multiple fractions of ionizing radiation in human A431 squamous cell carcinoma. Epidermal growth factor receptor. International Journal of Radiation Oncology, Biology, Physics 2003; 55(3)713–23
   PubMed Web of Science ®Google Scholar
• Nyati M. K., et al. Radiosensitization by Pan ErbB Inhibitor CI-1033 in Vitro and in Vivo. Clin. Cancer Res. 2004; 10(2)691–700
   PubMed Web of Science ®Google Scholar
• Zhou H., et al. Effects of the EGFR/HER2 kinase inhibitor GW572016 on EGFR- and HER2-overexpressing breast cancer cell line proliferation, radiosensitization, and resistance. International Journal of Radiation Oncology, Biology, Physics 2004; 58(2)344–52
   PubMed Web of Science ®Google Scholar
• Chinnaiyan P., et al. Mechanisms of Enhanced Radiation Response following Epidermal Growth Factor Receptor Signaling Inhibition by Erlotinib (Tarceva). Cancer Res. 2005; 65(8)3328–35
   PubMed Web of Science ®Google Scholar
• Dassonville O., et al. Expression of epidermal growth factor receptor and survival in upper aerodigestive tract cancer. J. Clin. Oncol. 1993; 11(10)1873–8
   PubMed Web of Science ®Google Scholar
• Rubin Grandis J., et al. Quantitative immunohistochemical analysis of transforming growth factor-alpha and epidermal growth factor receptor in patients with squamous cell carcinoma of the head and neck. Cancer 1996; 78(6)1284–92
   PubMed Web of Science ®Google Scholar
• Ang K. K., Andratschke N. H., Milas L. Epidermal growth factor receptor and response of head-and-neck carcinoma to therapy. Int. J. Radiat. Oncol. Biol. Phys. 2004; 58(3)959–65
   PubMed Web of Science ®Google Scholar
• Ang K. K., et al. Impact of epidermal growth factor receptor expression on survival and pattern of relapse in patients with advanced head and neck carcinoma. Cancer Res. 2002; 62(24)7350–6
   PubMed Web of Science ®Google Scholar
• Chung K. Y., et al. Cetuximab shows activity in colorectal cancer patients with tumors that do not express the epidermal growth factor receptor by immunohistochemistry. J. Clin. Oncol. 2005; 23(9)1803–10
   PubMed Web of Science ®Google Scholar
• Li S., et al. Structural basis for inhibition of the epidermal growth factor receptor by cetuximab. Cancer Cell 2005; 7(4)301–11
   PubMed Web of Science ®Google Scholar
• Bandyopadhyay D., et al. Physical interaction between epidermal growth factor receptor and DNA-dependent protein kinase in mammalian cells. J. Biol. Chem. 1998; 273(3)1568–73
   PubMed Web of Science ®Google Scholar
• Dittmann K., et al. Radiation-induced epidermal growth factor receptor nuclear import is linked to activation of DNA-dependent protein kinase. J. Biol. Chem. 2005; 280(35)31182–9
   PubMed Web of Science ®Google Scholar
• Lorch J. H., et al. Epidermal growth factor receptor inhibition promotes desmosome assembly and strengthens intercellular adhesion in squamous cell carcinoma cells. J. Biol. Chem. 2004; 279(35)37191–200
   PubMed Web of Science ®Google Scholar
• Huang S. M., Harari P. M. Modulation of radiation response after epidermal growth factor receptor blockade in squamous cell carcinomas: inhibition of damage repair, cell cycle kinetics, and tumor angiogenesis. Clin. Cancer Res. 2000; 6(6)2166–74
   PubMed Web of Science ®Google Scholar
• Viloria-Petit A., et al. Acquired resistance to the antitumor effect of epidermal growth factor receptor-blocking antibodies in vivo: a role for altered tumor angiogenesis. Cancer Res. 2001; 61(13)5090–101
   PubMed Web of Science ®Google Scholar
• Perrotte P., et al. Anti-epidermal growth factor receptor antibody C225 inhibits angiogenesis in human transitional cell carcinoma growing orthotopically in nude mice. Clin. Cancer Res. 1999; 5(2)257–65
   PubMed Web of Science ®Google Scholar
• Akimoto T., et al. Inverse relationship between epidermal growth factor receptor expression and radiocurability of murine carcinomas. Clin. Cancer Res. 1999; 5(10)2884–90
   PubMed Web of Science ®Google Scholar
• Sheridan M. T., et al. Potential indicators of radiosensitivity in squamous cell carcinoma of the head and neck. Radiat. Oncol. Investig. 1997; 5(4)180–6
   PubMedGoogle Scholar
• Peng D, et al. Anti-epidermal growth factor receptor monoclonal antibody 225 up-regulates p27kip1 and induces G1 arrest in prostatic cancer cell line DU145. Cancer Research 1996; 56: 3666–9
   PubMed Web of Science ®Google Scholar
• Huang S., Harari P. M. Modulation of radiation response after epidermal growth factor receptor blockade in squamous cell carcinomas: inhibition of damage repair, cell cycle kinetics, and tumor angiogenesis. Clinical Cancer Research 2000; 6: 2166–74
   PubMed Web of Science ®Google Scholar
• Huang S. M., Bock J. M., Harari P. M. Epidermal growth factor receptor blockade with C225 modulates proliferation, apoptosis, and radiosensitivity in squamous cell carcinomas of the head and neck. Cancer Res. 1999; 59(8)1935–40
   PubMed Web of Science ®Google Scholar
• Grandis J. R., et al. Constitutive activation of Stat3 signaling abrogates apoptosis in squamous cell carcinogenesis in vivo. Proc. Natl. Acad. Sci. USA 2000; 97(8)4227–32
   PubMed Web of Science ®Google Scholar
• Harari P. M., Huang S. M. Modulation of molecular targets to enhance radiation. Clin. Cancer Res. 2000; 6(2)323–5
   PubMed Web of Science ®Google Scholar
• Bonner J. A., et al. Enhanced apoptosis with combination C225/radiation treatment serves as the impetus for clinical investigation in head and neck cancers. J. Clin. Oncol. 2000; 18: 47S–53S, (21 Suppl)
   PubMed Web of Science ®Google Scholar
• Shin D. M., et al. Epidermal growth factor receptor-targeted therapy with C225 and cisplatin in patients with head and neck cancer. Clin. Cancer Res. 2001; 7(5)1204–13
   PubMed Web of Science ®Google Scholar
• Herbst R. S., et al. Phase II multicenter study of the epidermal growth factor receptor antibody cetuximab and cisplatin for recurrent and refractory squamous cell carcinoma of the head and neck. J. Clin. Oncol. 2005; 23(24)5578–87
   PubMed Web of Science ®Google Scholar
• Burtness B., et al. Phase III Randomized Trial of Cisplatin Plus Placebo Compared With Cisplatin Plus Cetuximab in Metastatic/Recurrent Head and Neck Cancer: An Eastern Cooperative Oncology Group Study. J. Clin. Oncol. 2005; 23(34)8646–54
   PubMed Web of Science ®Google Scholar
• Kies M. S., et al. EGFR expression by immunohistochemistry (IHC) and response to chemotherapy and cetuximab in squamous cell carcinoma of the head and neck (SCCHN). J. Clin Oncol 2007, ASCO Annual Meeting Proceedings Part I. Vol 25, No. 18S (June 20 Supplement), 2007: 6024
   Google Scholar
• Bourhis J., et al. Phase I/II study of cetuximab in combination with cisplatin or carboplatin and flourouracil in patients with recurrent or metastatic squamous cell carcinoma of the head and neck. J. Clin. Oncol. 2006; 24: 286–2872
   Google Scholar
• Vermorken J., et al. Cetuximab extends survival of patients with recurrent or metastatic SCCHN when added to first line platinum based therapy—results of a randomized phase III (EXTREME) study. ASCO Annual Meeting. 2007; 6091
   Google Scholar
• Hitt R., et al. Phase II study of combination cetuximab and weekly paclitaxel in patients with metastatic/recurrent squamous cell carcinoma of head and neck (SCCHN): Spanish head and neck cancer group (TTC). J. Clin Oncol. 2007; 25(18S)6012
   Google Scholar
• Chan A. T.C., et al. Multicenter, phase II study of cetuximab in combination with carboplatin in patients with recurrent or metastatic nasopharyngeal carcinoma. J. Clin. Oncol. 2005; 23: 3568–76
   PubMed Web of Science ®Google Scholar
• ImClone Systems, Inc. and Bristol Meyrs-Squibb Company. Erbitux(tm) (Cetuximab) package insert. ImClone systems, Inc., Branchburg, NJ 2006
   Google Scholar
• O'Neil B. H., et al. High incidence of cetuximab-related infuson reactions in Tennessee and North Carolina and the association with atopic history. J. Clin. Oncol. 2007; 25: 2644–8
   PubMedGoogle Scholar
• Monti M., et al. Complications of therapy and a diagnostic dilemma case : case 2. cutaneous toxicity induced by cetuximab. J. Clin. Oncol. 2003; 21: 4651–3
   PubMed Web of Science ®Google Scholar
• Segeart S., Van Cutsem E. Clinical signs, pathophysiology and management of skin toxicity during therapy with epidermal growth factor receptor inhibitors. Ann. Oncol. 2005; 16(9)1425–33
   PubMed Web of Science ®Google Scholar
• Pérez-Soler R., Delord J. P., Hapern A. HER1/EGFR Inhibitor-Associated Rash: Future Directions for Management and Investigation Outcomes from the HER1/EGFR Inhibitor Rash Management Forum. The Oncologist 2005; 10(5)345–56
   PubMed Web of Science ®Google Scholar
• Cunningham D., et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl. J. Med. 2004; 351(4)337–45
   PubMed Web of Science ®Google Scholar
• Saltz L., et al. The presence and intensity of the cetuximab-induced acne-like rash predicts increased survival in studies across multipole malignancies. Proc. Am. Soc. Clin. Oncol. 2003; 22(204), (abstr 817)
   Google Scholar
• Peréz-Soler R., Saltz L. Cutaneous adverse effects with HER1/EGFR-targeted agents: is there a silver lining?. J. Clin. Oncol. 2005; 23: 5235–46
   PubMed Web of Science ®Google Scholar
• Robert F., et al. Phase I study of anti-epidermal growth factor receptor antibody cetuximab in combination with radiation therapy in patients with advanced head and neck cancer. J. Clin. Oncol. 2001; 19(13)3234–43
   PubMed Web of Science ®Google Scholar
• Bonner J. A., et al. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. NEJM 2006; 354: 567–78
   PubMed Web of Science ®Google Scholar
• Pfister D. G., et al. Concurrent cetuximab, cisplatin, and concomitant boost radiotherapy for locoregionally advanced squamous cell head and nek cancer: a pilot phase II study of a new combined-modality paradigm. J. Clin. Oncol. 2006; 24: 1072–8
   PubMed Web of Science ®Google Scholar
• Wanebo H. J., et al. Phase II evaluation of cetuximab (C225) combined with induction paclitaxel and carboplatin followed by C225, paclitaxel, carboplatin, and radiation for stage III/IV operable squamous cancer of the head and neck JECOG, E2303). J. Clin. Oncol. 2007; 25(18S)6015
   Google Scholar